Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Literature
1.
De Castro J, Cobo M, Isla D, Puente J, Reguart N, Cabeza M, et al. Recommendations for radiological diagnosis and assessment of treatment response in lung cancer: a national consensus statement by the Spanish Society of Medical Radiology and the Spanish Society of Medical Oncology. Clin Transl Oncol. 2015;17:17–23.CrossRef
2.
Vansteenkiste J, De Ruysscher D, Eberhardt WEE, Lim E, Senan S, Felpip E, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):vi89–98.
3.
4.
Howington JA, Blum MG, Chang AC, Balekian AA, Murthy SC. Treatment of Stage I and II non-small cell lung cancer. Diagnosis and management of lung cancer, 3rd edn: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2013;143:e278S–313S.CrossRefPubMed
5.
Timmermans RD, Herman J, Chao LC. Emergence of stereotactic body radiation therapy and its impact on current and future clinical practice. J Clin Oncol. 2014;32:2847–54.CrossRef
6.
Corso CD, Park HS, Moreno AC, Kim AW, Yu JB. Husain ZA, et al. Stage I lung SBRT clinical practice patterns. Am J Clin Oncol. 2014 [Epub ahead of print].
7.
Huang K, Dahele M, Senan S, Guckenberger M, Rodrigues GB, Ward A, et al. Radiographic changes after lung stereotactic ablative radiotherapy (SABR)—can we distinguish recurrence from fibrosis? A systematic review of the literature. Radiother Oncol. 2012;102:335–42.CrossRefPubMed
8.
Huang K, Senthi S, Palma DA, Spoelstra FOB, Warner A, Slotman BJ, et al. High-risk CT features for detection of local recurrence after stereotactic ablative radiotherapy for lung cancer. Radiother Oncol. 2013;103:51–7.CrossRef
9.
Huang K, Palma DA. Follow-up of patients after stereotactic radiation for lung cancer. a primer for the nonradiation oncologist. J Thorac Oncol. 2015;10:412–9.CrossRefPubMed
10.
Jiang Z-Q, Yang K, Komaki R, Wei X, Tucker SL, Zhuang Y, et al. Long-term clinical outcome of intensity-modulated radiotherapy for inoperable non-small cell lung cancer: the MD Anderson experience. Int J Radiat Oncol Biol Phys. 2012;83:332–9.CrossRefPubMed
11.
Sura S, Gupta V, Yorke E, Jackson A, Amols H, Rosenzweig KE. Intensity-modulated radiation therapy for inoperable non-small cell lung cancer: The Memorial Sloan-Kettering Cancer Center (MSKCC) experience. Radiother Oncol. 2008;87:17–23.CrossRefPubMedCentralPubMed
12.
Van Baardwijk A, Reymen B, Wanders S, Borger J, Öllers M, Dingemans A-MC, et al. Mature results of a phase II trial on individualized accelerated radiotherapy based on normal tissue constrains in concurrent chemo-irradiation for Stage III non-small cell lung cancer. Eur J Cancer. 2012;48:2339–46.CrossRefPubMed
13.
Ji K, Zhao LJ, Liu WS, Liu ZY, Yuan ZY, Pang QS, Wang J, et al. Simultaneous integrated boost intensity-modulated radiotherapy for treatment of locally advanced non-small-cell lung cancer: a retrospective clinical study. Br J Radiol. 2014;87:20130562.CrossRefPubMedCentralPubMed
14.
Han D, Qin Q, Hao S, Huang W, Wei Y, Zhang Z, et al. Feasibility and efficacy of simultaneous integrated boost intensity-modulated radiation therapy in patients with limited-disease small cell lung cancer. Radiat Oncol. 2014;9:280.CrossRefPubMedCentralPubMed
Metadata
Title
Current radiation therapy techniques for lung cancer and its importance for suitable radiological assessment of treatment response in lung cancer
Author
J. J. Cabrera Rodríguez
Publication date
01-06-2015
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 6/2015
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-015-1286-y

Other articles of this Issue 6/2015

Clinical and Translational Oncology 6/2015 Go to the issue

Research Article

Impairment of vascularization of the surface covering epithelium induces ischemia and promotes malignization: a new hypothesis of a possible mechanism of cancer pathogenesis

Research Article

Involvement of RalB in the effect of geranylgeranyltransferase I on glioma cell migration and invasion

Educational Series – Red Series

Giant cell tumour of bone: new treatments in development

Research Article

CMTM5 is reduced in prostate cancer and inhibits cancer cell growth in vitro and in vivo

Research Article

The NanoString-based multigene assay as a novel platform to screen EGFR, HER2, and MET in patients with advanced gastric cancer

Research Article

Effects of zoledronate on the radiation-induced collagen breakdown: a prospective randomized clinical trial
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits